No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102
Percheron Therapeutics (ASX:PER) said that the World Health Organization chose avicursen as the proposed international nonproprietary name for its investigational drug candidate, ATL1102, according to
Shareholders Have Faith in Loss-making Percheron Therapeutics (ASX:PER) as Stock Climbs 26% in Past Week, Taking Five-year Gain to 142%
Percheron Therapeutics Target Price Cut 10% to A$0.27/Share by Wilsons>PER.AU
Percheron Therapeutics Target Price Cut 10% to A$0.27/Share by Wilsons>PER.AU
No Data